Solid Biosciences
Business Services · Massachusetts, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
500 Rutherford Ave Fl 3, Charlestown, Ma...Phone Number
(617) 337-4680Website
www.solidbio.comRevenue
$21.1 MillionStock Symbol
SLDBIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
3
1
1
2
2
1
About Solid Biosciences
Solid Biosciences is a life sciences company focused on advancing a portfolio of gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy (Duchenne), SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia (CPVT), AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy, and additional assets for the treatment of fatal cardiac diseases. Solid is advancing its diverse pipeline across rare neuromuscular and cardiac diseases, bringing together experts in science, technology, disease management, and care. Patient-focused and founded by those directly impacted, Solids mandate is to improve the daily lives of patients living with these devastating diseases.Explore more
Solid Biosciences Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Solid Biosciences your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Check out if Solid Biosciences is spiking on competitors!
Solid Biosciences, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Solid Biosciences has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Solid Biosciences launches new products
Earning: See what the market has to say on Solid Biosciences recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Solid Biosciences
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Solid Biosciences had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Solid Biosciences has new funding data
Recommended Actions
Reach out to Masked Content who joined Solid Biosciences as Masked Content
Find more new buyers
Compare Similar Companies to Solid Biosciences
Compare insights from companies similar to Solid Biosciences, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Solid Biosciences is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Solid Biosciences is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Solid Biosciences.
Solid Biosciences financials insights
Gather financial insights about Solid Biosciences, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2018
Stock Offering
$125M
2020
Share Placement
$90M
2026
Stock/Share Issuance
$240M
Solid Biosciences Tech Stack
A closer look at the technologies used by Solid Biosciences
See more technologies
Most Recent Scoops
Open Position
Open Position
Open Position
Open Position
Person-Based
Business Finance, Finance, Financing & Debt
Solid Biosciences News & Media
Solid Biosciences to Participate at Upcoming Investor Conferences
CHARLESTOWN, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced participation in the following investor conferences:Solid Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Updates
- Duchenne (SGT-003): SGT-003 has been generally well tolerated in the Phase 1/2 INSPIRE DUCHENNE clinical trial, with 53 participants dosed as of August 4, 2026 -Solid Biosciences and NanoMosaic Announce Co-Marketing Agreement to Advance Gene Therapy Delivery and Analytics
Advanced Delivery. True Empty/Partial/Full Analytics. Greater Confidence for Gene Therapy Developers. Agreement brings together Solid's POLARIS-101™ (AAV-SLB101) next-generation capsid and NanoMosaic's FDA AMT-designated Tessie™ platform to provide gene therapy developers enhanced access...Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CHARLESTOWN, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced a grant of 6,580 restricted stock units (“RSUs”) to one newly hired employee.
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Solid Biosciences
Sign Up For FreeTo access detailed company insights
Solid Biosciences is a life sciences company focused on advancing a portfolio of gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy (Duchenne), SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia (CPVT), AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy, and add... Read More
